Ravi Viswanathan has bought stock on 18 days since Jan 2016

Ravi Viswanathan is a 10% owner of Adaptimmune Therapeutics Plc (ADAP), reporting his holdings to the U.S. Securities and Exchange Commission with a mailing address in Timonium, Maryland.( In addition to his insider position at Adaptimmune, he has also been disclosed as a significant shareholder in other biopharmaceutical companies, including PhaseBio Pharmaceuticals Inc.( These filings reflect his role as a substantial investor rather than an officer or director of Adaptimmune.(

Professionally, Viswanathan is the Founder and Managing Partner of NewView Capital (NVC), a venture growth firm with approximately $3B+ under management that invests in high‑potential technology companies through primary, secondary, and hybrid capital structures.( Before founding NewView Capital in 2018, he was a General Partner at New Enterprise Associates (NEA), where he led investments in notable companies such as Braintree, MuleSoft, GlobalLogic, TeleAtlas, Cyence, Acquia, Scout, Plaid, and Forter.( His earlier career includes roles at Goldman Sachs’ Private Equity Group, McKinsey & Company, and Raychem Corporation.( Viswanathan holds an MBA from the Wharton School, a PhD in Chemical Engineering from the University of California, Santa Barbara, and a BS in Bioengineering from the University of Pennsylvania, and he serves on the Wharton Executive Alumni Board.(

Written by Perplexity from public sources.